Genetic Clues for Skin Cancer Therapies Jacksonville FL

Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations. Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma.

Rehbein, Harold M MD - Rehbein Harold M MD
(904) 730-0078
5757 Booth Rd, #200
Jacksonville, FL
 
Schiavone, Frank E MD - North Florida Dermatology
(904) 354-4488
836 Prudential Dr, #1507
Jacksonville, FL
 
Pearl Chu Kwong, MD
(904) 390-3600
807 Childrens Way
Jacksonville, FL
Specialties
Dermatology
Gender
Female
Education
Medical School: Univ Of Alberta, Fac Of Med, Edmonton, Alb, Canada
Graduation Year: 1990

Data Provided by:
Bernhardt Michael J MD
(904) 387-4991
2054 Park St
Jacksonville, FL
 
Anne Laurelle Bernstein, MD
(904) 308-4196
1800 Barrs St
Jacksonville, FL
Specialties
Dermatology, Dermatopathology
Gender
Female
Education
Medical School: Med Univ Of Sc Coll Of Med, Charleston Sc 29425
Graduation Year: 1995

Data Provided by:
Pearl Chu Kwong, MD
(904) 390-3490
807 Childrens Way
Jacksonville, FL
Specialties
Dermatology
Gender
Female
Education
Medical School: Univ Of Alberta, Fac Of Med, Edmonton, Alb, Canada
Graduation Year: 1990

Data Provided by:
Harold Martin Rehbein, MD
(904) 730-0078
5757 Booth Rd Ste 200
Jacksonville, FL
Specialties
Dermatology
Gender
Male
Education
Medical School: Univ Of Wi Med Sch, Madison Wi 53706
Graduation Year: 1968

Data Provided by:
Frank Edward Schiavone, MD
(904) 354-4488
1541 Riverside Ave
Jacksonville, FL
Specialties
Dermatology
Gender
Male
Education
Medical School: Hahnemann Univ Sch Of Med, Philadelphia Pa 19102
Graduation Year: 1979

Data Provided by:
Dr.Scott Warren
(904) 296-1313
6890 Belfort Oaks Place
Jacksonville, FL
Gender
M
Education
Medical School: Univ Of Fl Coll Of Med
Year of Graduation: 1986
Speciality
Dermatologist
General Information
Accepting New Patients: Yes
RateMD Rating
4.3, out of 5 based on 3, reviews.

Data Provided by:
Michael Jay Bernhardt, MD
(904) 387-4991
2054 Park St
Jacksonville, FL
Specialties
Dermatology
Gender
Male
Education
Medical School: Emory Univ Sch Of Med, Atlanta Ga 30322
Graduation Year: 1980

Data Provided by:
Data Provided by:

Genetic Clues for Skin Cancer Therapies

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations.

Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma. Their study is published in the September issue of the journal Nature Genetics.

"We have found what appears to be an Achilles' heel of a sizable share of melanomas," Samuels, an investigator in the cancer genetics branch of the institute's Division of Intramural Research, said in a NIH news release.

The PTK family includes many genes that, when mutated, promote many types of cancer, including brain, gastric and lung malignancies, according to background information provided in the news release. In the new NIH study, one PTK gene that appeared particularly suspicious was the ERBB4 gene. Scientists found ERBB4 mutations in 19 percent of patients' tumors, making it the most frequently mutated PTK gene in melanoma. Additional lab studies found that melanoma cells with the ERBB4 defect were dependent on the mutant gene for their growth.

The researchers also found that two additional PTK genes -- FLT1 and PTK2B -- were mutated in about 10 percent of the tumor samples.

The discoveries could open up new avenues for therapies. For example, the researchers discovered that melanoma cells grew much more slowly when exposed to lapatinib (Tykerb), a chemotherapy drug that inhibits ERBB4. Lapatinib is already in use by some breast cancer patients. The NIH team is planning a clinical trial using lapatinib in patients with metastatic melanoma harboring ERBB4 mutations.

"Though additional work is needed to gain a more complete understanding of these genetic mutations and their roles in cancer biology, our findings open the door to pursuing specific therapies that may prove useful for the treatment of melanoma with ERBB4 mutations," Samuels stated.

More information

The American Cancer Society has more on melanoma.

SOURCE: U.S. National Institutes of Health, news release, Aug. 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Mailing Address:
Jacksonville Magazine
1261 King St.
Jacksonville, FL 32204
TEL: (904) 389-3622
FAX: (904) 389-3628
E-mail: mail@jacksonvillemag.com